Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT1000 HPV 14-valent vaccine Phase II in healthy women 18–45
CTR20212245Phase 2Completed
- Sponsor
- Beijing Nuoning Biotechnology
- Start
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant 14-valent human papillomavirus vaccine in human papillomavirus infection, sponsored by Beijing Nuoning Biotechnology. Started Sep 2021; status: completed.
02
Drugs
recombinant 14-valent human papillomavirus vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on CTR20212245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212245.